Comparison of the antiproteinuric effects of the calcium channel blockers benidipine and amlodipine administered in combination with angiotensin receptor blockers to hypertensive patients with stage 3–5 chronic kidney disease-Reference-Cited by-同舟云学术

Comparison of the antiproteinuric effects of the calcium channel blockers benidipine and amlodipine administered in combination with angiotensin receptor blockers to hypertensive patients with stage 3–5 chronic kidney disease

Published:2009-02-27 Issue:4 Volume:32 Page:270-275
ISSN:0916-9636
Container-title:Hypertension Research
language:en
Short-container-title:Hypertens Res

Author:

Abe Masanori,Okada Kazuyoshi,Maruyama Takashi,Maruyama Noriaki,Matsumoto Koichi

Publisher

Springer Science and Business Media LLC

Subject

Cardiology and Cardiovascular Medicine,Physiology,Internal Medicine

Link

http://www.nature.com/articles/hr200911.pdf

Reference29 articles.

1. Peterson JC, Adler S, Burkart JM, Greene T, Hebert LA, Hunsicker LG, King AJ, Klahr S, Massry SG, Seifter JL . The modification of diet in renal disease study group: blood pressure control, proteinuria, and the progression of renal disease. Ann Intern Med 1995; 123: 754–762.

2. De Leeuw PW, Thijs L, Birkenhager WH, Voyaki SM, Efstratopoulos AD, Fagard RH, Leonetti G, Nachev C, Petrie JC, Rodicio JL, Rosenfeld JJ, Sarti C, Staessen JA, Systolic Hypertension in Europe (Syst-Eur) Trial Investigators. Prognostic significance of renal function in elderly patients with isolated systolic hypertension: results from the Syst-Eur trial. J Am Soc Nephrol 2002; 13: 2213–2222.

3. Marin R, Gorostidi M, Fernandez-Vega F, Alvarez-Navascues R . Systemic and glomerular hypertension and progression of chronic renal disease: the dilemma of nephrosclerosis. Kidney Int 2005; 99: S52–S56.

4. Viberti G, Wheeldon MN, MicroAlbuminuria Reduction with VALsartan (MARVAL) Study Investigators. Microalbuminuria reduction with valsartan in patients with type 2 diabetes mellitus: a blood pressure-independent effect. Circulation 2002; 106: 672–678.

5. Lewis EJ, Hunsicker LG, Clarke WR, Berl T, Pohl MA, Lewis JB, Ritz E, Atkins RC, Rohde R, Raz I, Collaborative Study Group. Renoprotective effect of angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001; 345: 851–860.

Cited by 36 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. N-/T-Type vs. L-Type Calcium Channel Blocker in Treating Chronic Kidney Disease: A Systematic Review and Meta-Analysis;Pharmaceuticals;2023-02-22

2. Efficacy of Cilnidipine (L/N-type Calcium Channel Blocker) in Treatment of Hypertension: A Meta-Analysis of Randomized and Non-randomized Controlled Trials;Cureus;2021-11-22

3. An antihypertensive agent benidipine is an effective neuroprotective and antiepileptic agent: an experimental rat study;Neurological Research;2021-07-05

4. Effectiveness and Effect on Renal Parameters of Amlodipine vs. Other Dihydropyridine Calcium Channel Blockers in Patients with Essential Hypertension: Retrospective Observational Study Based on Real-World Evidence from Electronic Medical Records;Cardiology and Therapy;2021-06-11

5. Dihydropyridine calcium channel blockers for the renoprotective therapy of hypertensive patients with chronic kidney disease;Nephrology (Saint-Petersburg);2021-02-13